Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported consolidated revenue of ₹15,056 million for Q1FY26, up 7% year-on-year from ₹14,017 million in Q1FY25. Profit after tax surged 50% YoY to ₹2,155 million (PAT margin expanded to 14% from 10%), while EBITDA grew 39% YoY to ₹3,678 million with margins improving to 24% from 19%. On a standalone basis, revenue rose to ₹10,388 million and PAT climbed about 21% YoY to ₹2,693 million. Growth was led by Europe (+29%) and Canada/Australia/NZ (+65%), while the USA market dipped 2%. European subsidiary Cenexi turned in an EBITDA breakeven of €0.9 million versus a €3 million loss a year ago, helped by cost optimisation and new tech-transfer products. The auditor Deloitte Haskins & Sells issued an unmodified (clean) limited review report.
Strong margin expansion and PAT growth should be viewed positively by investors, signalling improving profitability and a turnaround at the loss-making Cenexi unit. However, the slight revenue dip in the key USA market warrants monitoring. Overall, the print is supportive for the stock in the near term.